page banner


PARPrion HRD Test

HapOnco® PARPrion HRD Test


Product Overview

HapOnco® PARPrion HRD Test is an NGS assay for guiding the use of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) treatment. This comprehensive test evaluates a range of factors related to homologous recombination repair genes, including BRCA1/2, loss of heterozygosity (LOH), telomeric allelic imbalance (TAI) and large-scale state transitions (LST). HapOnco® PARPrion HRD Test therefore improves the likelihood of identifying cancer patients who may benefit from PARPi.


Product Advantages

(1) Offering a comprehensive HRD assessment, identifying cancer patients who may benefit from PARPi, compared to genetic testing products that only cover BRCA mutations.
(2) Tailored HRD probes for the Chinese population with excellent uniformity and stable capture efficiency.


Applicable Population

Patients diagnosed with ovarian, breast, prostate and pancreatic cancers, as well as solid tumor patients who have shown poor response to conventional therapies and are seeking to benefit from PARPi treatment.